linjc16/ctgov huggingface dataset:
Electrode Placement in Electrical Velocimetry

Study Overview
=================
Brief Summary
-----------------
Electrical velocimetry (EV) is one of the latest adaptions of impedance cardiography showing diverging results. With electrode position being a suspected factor influencing measurement accuracy or reproducibility for impedance cardiography in general, no data is currently available on altering the gap of the two lower electrodes in EV. Reference values were determined using the non-invasive gold-standard cardiac magnetic resonance imaging (CMR).

Official Title
-----------------
Influence of Electrode Placement on Electrical Velocimetry Cardiac Output Measurements

Conditions
-----------------
Cardiovascular Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: indication for CMR Exclusion Criteria: pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients undergoing CMR<br>Assessment of hemodynamic function using: CMR EV with an inter-electrode gap (lower pair) of 5 cm EV with an inter-electrode gap (lower pair) of 15 cm | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| difference between CMR and EV cardiac output measurements |  | 45 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| difference between two consecutive EV cardiac output measurements |  | 5 minutes |
Effect of Dietary Salt Supplemantation in Vasovagal Syncope Prophylaxis: A Clinical Trial

Study Overview
=================
Brief Summary
-----------------
Syncope is a syndrome consisting of a relatively short period of temporary and self-limited loss of consciousness caused by transient diminution of blood flow to the brain (most often the result of systemic hypotension). The objective of this study was to evaluate the effect of salt supplementation in vasovagal syncope prophylaxis.

Detailed Description
-----------------
Healthy volunteers without use of medicines with except contraceptives orals that met the exclusion criteria were consecutively enrolled in a randomized trial.

Official Title
-----------------
Effect of Dietary Salt Supplemantation in Vasovagal Syncope Prophylaxis: A Clinical Trial

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Behavioral: Salt Supplementation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy volunteers Exclusion Criteria: Use medicines Previous diseases Incapacity of to understand and to sign the term consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Salt Supplementation|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate the effectiveness of the salt supplementation in the prophylaxis of the vasovagal syncope |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate the supplementation salt increases the orthostatic tolerance |  |  | 
| Analyze the supplementation salt increases the plasmatic volume |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Salt supplementation, Vasovagal syncope, Orthostatic tolerance, Healthy volunteers
Digital Intervention for Ethnic Groups in Transplantation (DIGIT)

Study Overview
=================
Brief Summary
-----------------
Study Title Digital intervention for Ethnic Groups in Transplantation (DiGiT) Internal ref. no. (or short title) DiGiT Study Design Observational cohort study Study Participants 90 Planned Size of Sample (if applicable) 30 Follow up duration (if applicable) 2 years Planned Study Period 2 years Research Question/Aim(s) To produce, test and pilot a video-based intervention about living donor kidney transplantation in Black, Asian & Minority ethnic (BAME) community in United Kingdom. Embedded within this is an ambassador training. Study the long term psychological impact of BAME donors following donation.

Official Title
-----------------
Digital Intervention for Ethnic Groups in Transplantation (DIGIT)

Conditions
-----------------
Live Donors, Ethnic Minorities, Transplantation

Intervention / Treatment
-----------------
* Behavioral: Video and questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults >18 years of age Belong to a BAME community only for phase 1-3, in phase 4 all past and future donors regardless of ethnicity would be eligible. Be a community member, past donor, past recipient of a transplant, healthcare professional or be on the waiting list for a transplant. Exclusion Criteria: Anyone less than 18 years of age Unable to consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Digital intervention<br> | Behavioral: Video and questionnaire<br>* Potential donors would be shown a video and asked to complete a questionnaire to capture change in attitude towards donation.<br>* Other names: Digital intervention;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Magnitude of the change in score assessing knowledge of LDKT by study questionnaire | Change in attitudes and knowledge of LDKT will be assessed by study questionnaire and the magnitude in change will be quantified by the change in score following digital intervention | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Magnitude of change in QOL score pre donation to 1 year post donation | Change in QOL as measured by SF 36 in the 3 months preceding donation and 1 year post donation. | 2 years |
Efficacy of Bispectral Index Monitoring for Midazolam and Meperidine Induced Sedation During Endoscopic Submucosal Dissection

Study Overview
=================
Brief Summary
-----------------
Background: Endoscopic submucosal dissection (ESD) usually requires adequate level of sedation due to lengthy and uncomfortable procedure. Propofol induced sedation with bispectral index (BIS) monitoring has been reported to lead to higher satisfaction of patients and endoscopists during ESD. However, there is no data about efficacy of midazolam and meperidine induced sedation with BIS monitoring during ESD. This study was to evaluate whether midazolam and meperidine induced sedation with BIS monitoring could improve the satisfaction and reduce the dose of midazolam and meperidine during ESD.

Official Title
-----------------
Efficacy of Bispectral Index Monitoring for Midazolam and Meperidine Induced Sedation During Endoscopic Submucosal Dissection

Conditions
-----------------
Gastric Adenoma, Gastric Cancer

Intervention / Treatment
-----------------
* Device: bispectral index monitoring


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: gastric adenomas, differentiated-type gastric cancers greater than 30 mm in diameter without ulceration and gastric cancers up to 30 mm with ulceration, or minute submucosal invasion Exclusion Criteria: if they were under 18 years of age had an ASA classification of 4-5 were pregnant had a history of stroke or an allergy to sedative drugs.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: BIS group<br> | Device: bispectral index monitoring<br>* parameter monitoring of bispectral index<br>|
| Placebo Comparator: non BIS group<br> | Device: bispectral index monitoring<br>* parameter monitoring of bispectral index<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the satisfaction of patients and endoscopist in midazolam and meperidine induced sedation with BIS monitoring during ESD |  | within the one day after ESD | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the dose of midazolam and meperidine during ESD with BIS monitoring |  | within one hour after ESD | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
gastric adenoma, early gastric cancer
Mallet Finger Splinting Study

Study Overview
=================
Brief Summary
-----------------
Do patients that night splint for 1 month after 6-8 weeks of continuous splinting for a mallet injury have the same extensor lag 4 months after initiating treatment as patients that do not perform night splinting? Secondary Question: Is night splinting a predictor of DASH score or patient satisfaction (on a 5-Point Likert scale)?

Official Title
-----------------
Night Splinting After 6 to 8 Weeks of Continuous Splinting for Mallet Finger

Conditions
-----------------
Mallet Finger

Intervention / Treatment
-----------------
* Procedure: night splinting


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All adult, English-speaking patients in the practice of Dr. Jesse Jupiter, Dr. Chaitanya Mudgal, or Dr. David Ring electing splint treatment for mallet deformity will be invited to enroll on their follow-up visit 6-8 weeks after initiating splint treatment. Exclusion Criteria: Open lesions Mallet fracture more than 2 weeks old Mallet fracture with subluxation of the distal interphalangeal joint.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: no night splinting<br> | |
| Active Comparator: night splinting<br>Night Splinting for 4 weeks after removal of initial cast | Procedure: night splinting<br>* splint finger at night for 4 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Extensor Lag | Null Hypothesis: Patients that night splint for 1 month after 6-8 weeks of continuous splinting for a mallet injury have the same extensor lag 4 months after initiating treatment as patients that do not perform night splinting. | 4 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| DASH score | Secondary Study Questions: Is night splinting a predictor of DASH score or patient satisfaction (on a 5-Point Likert scale)? | 4 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Mallet Finger splinting
Post-Market Study of Robotic-Arm Assisted Total Knee Arthroplasty

Study Overview
=================
Brief Summary
-----------------
This is an early user evaluation of the robotic-assisted total knee arthroplasty platform. The objective of this surgeon group is to capture data on the defined objectives and provide Stryker with feedback.

Official Title
-----------------
Post-Market Study of Robotic-Arm Assisted Total Knee Arthroplasty

Conditions
-----------------
Osteoarthritis, Knee

Intervention / Treatment
-----------------
* Device: Total Knee Arthroplasty using Manual Instrumentation
* Device: Total Knee Arthroplasty using Robotic Arm


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient requires primary total knee surgery Patient is willing and able to comply with postoperative follow-up requirements and self evaluations Patient is willing to sign an IRB approved informed consent Patient is at least 18 years of age Exclusion Criteria: Patient has a BMI > 50 Patient is skeletally immature Patient has an active infection or suspected infection in or about the joint Bone stock that is inadequate to support fixation of the prosthesis Neuromuscular disorders, muscular atrophy or vascular deficiency in the affected limb rendering the procedure unjustified. Patients with mental or neurological conditions which may be incapable of following instructions. Blood supply limitations Collateral ligament insufficiency. Patients with prior HTOs or Unis.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Manual instrument total knee replacement<br> | Device: Total Knee Arthroplasty using Manual Instrumentation<br> <br> |
| Active Comparator: Robitic arm total knee replacement<br> | Device: Total Knee Arthroplasty using Robotic Arm<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Component alignment | CT scan measurement | 6 weeks post knee arthroplasty |
Study of Topical Ocular PAN-90806 in PDR

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to assess the safety and tolerability of topical ocular PAN-90806 in patients with proliferative diabetic retinopathy.

Official Title
-----------------
A Phase 1 Open-Label, Single-Center Study to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients With Proliferative Diabetic Retinopathy (PDR)

Conditions
-----------------
Diabetic Retinopathy

Intervention / Treatment
-----------------
* Drug: PAN-90806 Ophthalmic Solution


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged 18 years or older with type 1 or type 2 diabetes Proliferative diabetic retinopathy (PDR) in study eye retina with or without diabetic macular edema (DME) involving the center of the macula Demonstrate the ability, or have a family member who is willing and able, to instill topical ocular drops in the study eye Exclusion Criteria: Current or recent use (within the last 3 months) of anti-vascular endothelial growth factors (anti-VEGF) in either eye; Uncontrolled hypertension despite use of antihypertensive medications Unwillingness to refrain from wearing contact lenses for the duration of the study. Participation in any investigational drug or device study, systemic or ocular, within past 3 months Women who are pregnant or nursing Known serious allergies or hypersensitivity to the fluorescein dye used in angiography or to the components of the PAN-90806 formulation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: PAN-90806 Ophthalmic Solution<br>PAN-90806 Ophthalmic Solution taken daily for 8 weeks. | Drug: PAN-90806 Ophthalmic Solution<br> <br> * Other names: PAN-90806 Eye Drops;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Patients with Adverse Events | Safety will be assessed based upon the incidence of all adverse events, ocular and systemic | 2 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The mean change in best-corrected visual acuity from baseline |  | Week 8 | 
| Change in preretinal neovascularization | descriptive observations of the presence and extent as determined by ultra-wide field fluorescein angiography (FA) and color fundus photography (FP) | Week 4 and Week 8 | 
| The mean number of rescue treatments during the study |  | Week 8 | 
| Time to first rescue treatment |  | up to Week 8 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Proliferative Diabetic Retinopathy
Conservative Treatment of Esotropia in Children up to 3 Years Old

Study Overview
=================
Brief Summary
-----------------
The objective of this prospective study is the treatment of esotropia by prescribing the full precise optical correction of refractive errors in children up to 3 years old.

Detailed Description
-----------------
This investigation includes children with esotropia associated with hyperopia, hypermetropic astigmatism, myopia, myopic astigmatism and minor ametropias. All children are prescribed full optical correction of refractive errors with special attention to astigmatism up to 0.5 Dpt to achieve maximal clear image on the retina of both eyes.If necessary, direct occlusion or penalization were administered to the children. The investigators suggest that this approach will give good results in the treatment of esotropia.

Official Title
-----------------
Prescription of Full Optical Correction in Refractive Errors to Treat Esotropia in Children up to 3 Years Old

Conditions
-----------------
Esotropia

Intervention / Treatment
-----------------
* Other: Prescription of spectacles


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Within the age of 3 months to 3 years (inclusive infantile esotropia) Patients with constant or periodic esotropia and with revealed angle of deviation 5 degrees or over by Hirschberg test Patients with refractive errors (inclusive minor ametropias from 0.5 Dptr) Exclusion Criteria: Age above 3 years Patients with neurological diseases and paralytic strabismus

Ages Eligible for Study
-----------------
Minimum Age: 3 Months
Maximum Age: 3 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: spectacles<br>Esotropia is treated by full optical correction (spectacles prescription) in all children with refractive errors. Special attention is paid to astigmatism up to 0.5 Dptr. Intervention: Prescription of spectacles | Other: Prescription of spectacles<br>* All children are prescribed full optical correction of refractive errors with special attention to astigmatism up to 0.5 Dptr to achieve maximal clear image on the retina of both eyes.If necessary, direct occlusion or penalization are administered to the children.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The angle of deviation | The absolute success is defined as restored symmetrical eye position.Qualified success is considered as reduction of the angle of deviation. Patients are examined 24 months later to assess outcome of treatment. | 2 years |
Analysis of Factors and Treatment Related to Chronic Cough After Pulmonary Resection

Study Overview
=================
Brief Summary
-----------------
Surgical resection is the primary treatment for pulmonary tumors. Surgeons has been frequently concerned about effectiveness, safety, and minimal invasive techniques. However, persistent cough, one of the most common complications of lung surgery, has received insufficient attention. This study set out to investigate the risk factors and treatment related to persistent cough after pulmonary resection.

Official Title
-----------------
Analysis of Factors and Treatment Related to Chronic Cough After Pulmonary Resection

Conditions
-----------------
Persistent Cough, Pneumonectomy, Lung Neoplasms

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who received pulmonary resection; 18-to 85-year-old; Pathologically diagnosed as NSCLC or benign tumor. Exclusion Criteria: Multiple malignancy in other parts of body; Refuse to participate in this study; Other situations evaluated by investigators not meet the enrollment.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurence rate of persistent cough after pulmonary resection | Occurence rate of persistent cough after pulmonary resection | Persistent cough after pulmonary resection is monitored from the time of surgery, up to 12 months. |